Loading, Please Wait...
SANTA CLARA, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a medical device company that is pioneering the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced the company will be participating in the upcoming Canaccord Genuity Musculoskeletal Conference in Las Vegas, Nevada.
SI-BONE’s management is scheduled to present on Tuesday, March 12, 2019 at 2:30 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.si-bone.com.
SI-BONE is a medical device company that pioneered the iFuse Implant System, a minimally invasive surgical system for fusion of the sacroiliac joint to treat sacroiliac joint dysfunction. The SI joint is believed to be the last major joint with a clinically proven surgical treatment. The iFuse Implant, commercially available since 2009, is believed to be the only SI joint fusion device supported by multiple prospective clinical studies showing improved pain, patient function and quality of life resulting from treatment. There are over 60 peer-reviewed publications supporting the safety, effectiveness, and biomechanical and economic benefits unique to the iFuse Implant. This body of evidence has enabled multiple government and private payers to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.
The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.
SOURCE SI-BONE, Inc.
Lynn Lewis or Carrie Mendivil